A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy
OBJECTIVES:
- Determine the effect of megestrol on weight in patients receiving radiotherapy for lung
cancer.
- Determine the quality of life of patients treated with this drug.
OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients
are stratified according to histology (non-small cell lung cancer vs small cell lung
cancer), and type of treatment (radiotherapy vs radiotherapy and non-cisplatin-containing
chemotherapy vs radiotherapy and cisplatin-containing chemotherapy). Patients are randomized
to one of two treatment arms.
All patients undergo thoracic radiotherapy beginning on week 1 and continuing for a total of
5-7 weeks.
- Arm I: Patients receive oral megestrol once daily beginning within the first 3 days of
radiotherapy and continuing until 12 weeks after the completion of radiotherapy.
- Arm II: Patients receive oral placebo once daily beginning within the first 3 days of
radiotherapy and continuing until 12 weeks after the completion of radiotherapy.
In both arms, quality of life is assessed at baseline, at the completion of radiotherapy,
and at 4, 8, 12, 16, and 20 weeks after the completion of radiotherapy.
Patients are followed at 4 and 8 weeks.
PROJECTED ACCRUAL: A total of 98 patients (49 per treatment arm) will be accrued for this
study.
Interventional
Primary Purpose: Supportive Care
Edward G. Shaw, MD
Study Chair
Comprehensive Cancer Center of Wake Forest University
United States: Federal Government
CDR0000069226
NCT00031785
September 2000
Name | Location |
---|---|
Comprehensive Cancer Center at Wake Forest University | Winston-Salem, North Carolina 27157-1082 |